Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2024-200914

Published: 2024

Journal Articles

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Blood (2024) 144 (Supplement 1): 4569.3.

https://doi.org/10.1182/blood-2024-200881

Published: 2024

Journal Articles

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Seok-Goo Cho, Tae Min Kim, Michal Taszner, Tsai-Yun Chen, Aafia Choudhry, Melanie Ufkin, Amulya Uppala, Ayesha Sabir, Hesham Mohamed, Srikanth Ambati, Emmanuel Bachy

Blood (2024) 144 (Supplement 1): 6302.

https://doi.org/10.1182/blood-2024-200770

Published: 2024

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobinemia mimicking plasma cell myeloma

Chih-Chieh Yen, Tsai-Yun Chen

Blood (2018) 132 (25): 2700.

https://doi.org/10.1182/blood-2018-07-863290

Published: 2018

Journal Articles

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Yi-Jiun Su, MD, Ming-Chung Kuo, MD, Chieh-Lin Teng, MD, Tsai-Yun Chen, MD, Ming-Chun Ma, MD, Pei-Ching Hsiao, MD, Ming-Chung Wang, MD, Tung-Huei Lin, MS, Wen-Li Hwang, MD, Chih-Cheng Chen, MD, Youngsen Yang, MD, Sung-Nan Pei, MD, Yen-Min Huang, MD, Sin-Syue Li, MD, Ming-Yang Lee, MD, Hung-I Cheng, MD, Lee-Yung Shih, MD

Blood (2017) 130 (Supplement 1): 1603.

https://doi.org/10.1182/blood.V130.Suppl_1.1603.1603

Published: 2017

Journal Articles

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Su-Peng Yeh, MD, Ming Yao, MD, Jih-Luh Tang, MD,PhD, Jin-Hwang Liu, MD PhD, Tzeon-Jye Chiou, MD, Tran-Der Tan, Po-Nan Wang, MD, Yeu-Chin Chen, MD, Wen-Li Hwang, MD, Ciyuan-jheng Wang, MD, Tsai-Yun Chen, MD, TA-Chih LIU, MD PhD, Ming-Sun Yu, MD, Tso-Fu Wang

Blood (2017) 130 (Supplement 1): 3229.

https://doi.org/10.1182/blood.V130.Suppl_1.3229.3229

Published: 2017

Journal Articles

Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Ching-Yuan Kuo, MD, Po-Nan Wang, MD, Wen Li Hwang, MD, Cheng-Hwai Tzeng, MD, Li-Yuan Bai, MD, Jih-Luh Tang, MD PhD, Ming-Chih Chang, MD, Sheng-Fung Lin, MD, Tsai-Yun Chen, MD, Yeu-Chin Chen, MD, Tran-Der Tan, MD, Chih-Yi Hseih, MD, Chinjune Lin, MD, Miljkovic Darko, MD, Chang Cheng-Shyong, MD

Blood (2015) 126 (23): 1593.

https://doi.org/10.1182/blood.V126.23.1593.1593

Published: 2015

Journal Articles

A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia

Suporn Chuncharunee, MD, Raymond SM Wong, MD, Ponlapat Rojnuckarin, MD PhD, Cheng-Shyong Chang, MD, Kian Meng Chang, MD, Meng-Yao Lu, MD, Wen-Li Hwang, MD, Liang Piu Koh, MD, Tsai-Yun Chen, MD, Anskar YH Leung, MD, Lalita Norasetthada, MD, Shih-Chung Wang, MD, Ming-Chih Chang, MD, Kang-Hsi Wu, MD, Surapol Issaragrisil, MD

Blood (2015) 126 (23): 1217.

https://doi.org/10.1182/blood.V126.23.1217.1217

Published: 2015

Journal Articles

Different Adverse Event Profiles and Significant Hematological Improvement Are Noted When Deferasirox Was Used in Adult Patients with Chronic Transfusion-Related Iron Overload in Taiwan: Results from a Prospective Observational Clinical Trial

Bor-Sheng Ko, Ming-Chih Chang, MD, Tzeon-Jye Chiou, MD, Te-Kau Chang, MD, Yeu-Chin Chen, MD, Sheng-Fung Lin, MD, Cheng-Shyong Chang, MD, Yin-Che Lu, MD, Su-Peng Yeh, MD, Tsai-Yun Chen, MD, Wei-Yu Chen, MD

Blood (2015) 126 (23): 4554.

https://doi.org/10.1182/blood.V126.23.4554.4554

Published: 2015

Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD

Blood (2014) 124 (21): 4544.

https://doi.org/10.1182/blood.V124.21.4544.4544

Published: 2014

Journal Articles

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

Hui-Jen Tsai, MD PhD, Ming-Chung Wang, MD, Sheng-Fung Lin, MD, Ya-Ping Chen, MD PhD, Hui-Hwa Hsiao, MD PhD, Ching-Yuan Kuo, MD, Li-Tzong Chen, MD PhD, Tsai-Yun Chen, MD

Blood (2014) 124 (21): 984.

https://doi.org/10.1182/blood.V124.21.984.984

Published: 2014

Journal Articles

Uveal melanoma with diffuse bone marrow involvement

Sheng-Yen Hsiao, Tsai-Yun Chen

Blood (2014) 124 (12): 1996.

https://doi.org/10.1182/blood-2014-05-573816

Published: 2014

Journal Articles

Targeting Aurora Kinases in Acute Lymphoblastic Leukemia

Ya-Ping Chen, Hui-Ju Lin, Kung-Chao Chang, Jiann-Shiuh Chen, Ming-Ying Tsai, Liang-Yi Hung, Tsai-Yun Chen

Blood (2012) 120 (21): 4907.

https://doi.org/10.1182/blood.V120.21.4907.4907

Published: 2012

NARROW

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobinemia mimicking plasma cell myeloma

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia

Different Adverse Event Profiles and Significant Hematological Improvement Are Noted When Deferasirox Was Used in Adult Patients with Chronic Transfusion-Related Iron Overload in Taiwan: Results from a Prospective Observational Clinical Trial

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

Uveal melanoma with diffuse bone marrow involvement

Targeting Aurora Kinases in Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only